Processa (NASDAQ: PCSA) R&D president receives 49 shares from RSU vesting

Rhea-AI Filing Summary

Processa Pharmaceuticals director and officer David Young, President of Research & Development, reported the vesting and distribution of restricted stock units into common stock on January 1, 2026. A total of 49 restricted stock units were converted at an exercise price of $0, resulting in 49 common shares acquired.

Following this transaction, Young holds 8,752 Processa common shares directly. He also has indirect beneficial ownership of common stock, including 1,242 shares through the Young-Plaisance Revocable Trust, 432 shares through family entities, and 742 shares through CorLyst, LLC. The filing describes the event as a distribution of vested restricted shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Young David

(Last) (First) (Middle)

C/O PROCESSA PHARMACEUTICALS, INC.

601 21ST STREET SUITE 300

(Street)

VERO BEACH FL 32960

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Processa Pharmaceuticals, Inc. [ PCSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Pres. Research & Development

3. Date of Earliest Transaction (Month/Day/Year)
01/01/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/01/2026		M		49	A	$0(1)	8,752	D
Common Stock								1,242	I	By Young-Plaisance Revocable Trust
Common Stock								432	I	By Family Entities
Common Stock								742	I	By CorLyst, LLC

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0	01/01/2026		M			49	(1)	(1)	Common Stock	49	$0	0	D

Explanation of Responses:

1. Distribution of vested restricted shares.

	/s/ David Young by John J. Wolfel, as Attorney-in-Fact	02/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did PCSA’s David Young report on January 1, 2026?

David Young reported the vesting and distribution of 49 restricted stock units into 49 Processa common shares on January 1, 2026. The transaction used an exercise price of $0, reflecting a standard equity compensation conversion rather than an open-market purchase.

How many PCSA shares does David Young own directly after this Form 4?

After the reported transaction, David Young directly owns 8,752 shares of Processa Pharmaceuticals common stock. This figure represents his direct holdings following the conversion of 49 restricted stock units into common shares at an exercise price of $0.

What indirect PCSA shareholdings are reported for David Young on this Form 4?

The filing lists indirect holdings of Processa common stock for David Young, including 1,242 shares through the Young-Plaisance Revocable Trust, 432 shares through family entities, and 742 shares through CorLyst, LLC, in addition to his direct ownership.

What does transaction code “M” indicate in David Young’s PCSA Form 4?

Transaction code “M” indicates an exercise or conversion of a derivative security. In this case, 49 restricted stock units were converted into 49 shares of Processa common stock at an exercise price of $0, as part of an equity compensation arrangement.

What role does David Young hold at Processa Pharmaceuticals (PCSA)?

David Young is reported as both a director and an officer of Processa Pharmaceuticals, serving as President, Research & Development. His dual role and equity holdings align his interests with the company’s long-term performance and strategic development efforts.

How many restricted stock units remain after the reported PCSA transaction?

The filing shows 49 restricted stock units with an exercise price of $0 were converted, leaving 0 derivative securities beneficially owned in that specific RSU award. This reflects a full distribution of the vested restricted shares identified in the transaction.